Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are effective analgesic drugs. Recent studies have indicated a potential beneficial effect on long-term survival outcomes after cancer surgery but a negative impact on anastomotic leaks. The objective of this study was to objectively assess the implications of the perioperative NSAIDs use on anastomotic leaks and cancer recurrence. Methods: We searched PubMed, MEDLINE, Embase and Cochrane Library for publications up to mid-January 2017. Randomized controlled trials (RCTs) and observational studies in adults undergoing cancer surgery were included for quality assessment. We excluded animal studies, in vitro experiments and case reports. The selected sudies were graded using the Jadad score or Newcastle-Ottawa scale for RCTs and observational retrospective studies, respectively. Results: The systematic review identified 25 trials that explored the impact of NSAIDs on anastomotic leaks and 16 trials that assessed the association between perioperative NSAIDs and cancer recurrence. Meta-analyses were not performed because of high heterogeneity and low quality of the included studies. Conclusions: The literature is not conclusive on whether the use of NSAIDs is associated with anastomotic leaks after gastrointestinal cancer surgery. Also, the current evidence is equivocal regarding the effects of short-term NSAIDs on cancer recurrence after major cancer surgery. Three RCTs are being conducted to assess the impact of NSAIDs on cancer recurrence. There are no registered RCTs that are testing the hypothesis of whether the perioperative use of NSAIDs increases the rate of anastomotic leaks.
The current evidence suggests that the perioperative period plays a significant role in patients with potentially curable solid tumours. [1] [2] [3] It has been suggested that the analgesics used during and after surgery might not only have a major impact on short-term outcomes but also on long-term outcomes such as cancer recurrence. 4 5 Analgesic strategies for cancer surgery are evolving from the systemic administration of i.v. opioids via patient-controlled analgesia (IV-PCA) to the combination of regional analgesia techniques and systemic non-opioid analgesics (i.e. multimodal analgesia). [6] [7] [8] Non-steroidal anti-inflammatory drugs (NSAIDs), which include both traditional NSAIDs and cyclooxygenase (COX)-2-specific inhibitors (coxibs), have been demonstrated to play an important role in multimodal analgesia for oncological surgery.
A meta-analysis of randomized controlled trials (RCTs) demonstrates that NSAIDs reduce opioid consumption, vomiting and sedation by 30%, 32% and 29%, respectively. 9 Furthermore, the administration of NSAIDs is associated with improvement in the quality of recovery and satisfaction. 10 Hence, they are currently recommended for enhanced recovery after surgery protocols for gastrointestinal cancer surgery; however, several clinical studies have suggested an association between the use of NSAIDs and anastomotic leaks after gastrointestinal surgery. [11] [12] [13] [14] [15] [16] In the present systematic review, we assessed the evidence regarding the use of NSAIDs during oncological surgery and their impact on anastomotic leaks and cancer recurrence.
Methods

Literature search
Two independent series of database searches were performed covering each of the topics of the review: (1) NSAIDs and anastomotic leaks, and (2) NSAIDs and postsurgical cancer recurrence. The databases searched for each topic were Medline (Ovid), Embase (Ovid), Cochrane Library (Wiley) and the non-Medline portion of PubMed (NLM). These databases were searched from inception through to mid-January 2017. A medical librarian with more than 25 years of database-searching experience conducted all the literature searches.
The search strategies for both series of literature searches consisted of a combination of controlled vocabulary (e.g. MeSH) and keyword terms. NSAID-related terms were searched at both the drug class and individual drug name level and included common acronyms. Variations of anastomotic leak terms that were searched included anastomotic failure, dehiscence, complications, perforations and healing. The postsurgical cancer recurrence search strategy incorporated common surgical procedures in cancer patients, such as craniotomy, lobectomy, lumpectomy and prostatectomy. To help ensure no cancer recurrence records were missed, survival (cancer surgery or recurrence or survival or relapse or disease-free or progression free) and metastasis-related (metastasis or micrometastasis) search terms were added to the search strategies. Additional articles were retrieved by manually searching the reference lists in included studies as well as other review articles.
Inclusion and exclusion of trials
Inclusion criteria for studies that assessed anastomotic leaks included: (1) RCTs and observational cohort studies published in English language, (2) studies including adult patients, (3) reports including patients undergoing oncological surgery, (4) publications including treatment with a single dose or multiple doses of NSAIDs before (within 24 h from surgery), during or after surgery (within 30 days), and (5) investigations that reported anastomotic leak, cancer recurrence or survival endpoints as primary or secondary outcomes. Exclusion criteria: (1) animal studies, (2) in vitro studies, and (3) case reports. Also, studies that recruited both cancer and non-cancer patients and did not provide data on primary or secondary outcomes were not included. Outcome measures assessed for studies on anastomotic leaks included postoperative upper or lower gastrointestinal anastomotic leaks as assesed by radiological techniques or need for surgical re-intervention. Studies that did not report anastomotic leaks using these definitions were excluded.
Studies assessing the effects of NSAIDs on postoperative cancer outcomes such as cancer recurrence rate, recurrence-free survival, disease-free survival, cancer-specific survival and/or overall survival were included.
Selection of studies and quality assessment
Two authors (J.P.C. and V.G.) independently screened titles and abstracts for inclusion. A third author resolved any disagreements between the two reviewers. Included studies were assessed for quality using the Jadad score and NewcastleOttawa scale for RCTs and observational retrospective studies, respectively. The analysis included studies only graded as high quality (i.e. Jadad score 3 or Newcastle-Ottawa score 8). The information from each included study was extracted according to the list of outcome measures discussed above.
Results
Perioperative NSAIDs and anastomostic leaks
Two hundred and seventeen titles were retrieved from the literature search. Figure 1 illustrates the PRISMA flow diagram to detail the literature search and selection process. Of the 45 studies that were thoroughly reviewed, 25 studies were considered for quality assessment, which included nine RCTs or metaanalysis of RCTs and 16 observational trials. Seven studies were excluded because of low quality. The remaining studies were not included in a quantitative analysis because of the following issues: (1) mixed population of risk of anastomotic leaks (high risk vs low risk) and/or cancers (colorectal vs hypopharyngeal tumours), (2) anastomotic leak was not the primary outcome in any of the RCTs, and (3) inconsistent NSAIDs type, dose and duration of administration. While several observational studies did have anastomotic leaks as the primary outcome, only six reported the outcome of interest in cancer patients. The remaining studies included a mixed population of cancer and noncancer patients. Tables 1 and 2 contain the data extracted from each of the included studies.
Perioperative NSAIDs and cancer recurrence
A total of 550 titles were retrieved from the literature search. The PRISMA flow diagram to detail the literature search and selection process is included in Figure 2 . Of the 30 studies that were fully reviewed, 14 were excluded because they were narrative review articles, case reports or laboratory studies. Sixteen studies underwent quality assessment. Five studies were scored as low quality. Despite being high quality, the remaining studies did not enter into a quantitative analysis because they: (1) included different cancer histologies or tumour stages, and (2) did not consistently report on NSAIDs type, dose, time and duration of administration. Tables 3 and 4 contain the data extracted from each of the included studies.
Discussion
Perioperative NSAIDs and anastomostic leaks
Anastomotic leaks are surgical complications with an incidence varying between 1% and 30%. 50 51 These postoperative events are associated with prolonged hospitalizations and a high rate of re-admissions and 30 day mortality. [52] [53] [54] In fact, the 30 day mortality rate linked to anastomotic leaks can be as high as 15.2%. 27 55 Furthermore, the occurrence of anastomotic leaks appears to be related to reduced disease-free survival, more so after colon surgery than after rectal procedures. 56 57 Therefore, a large body of research has been focused on the identification of risk factors that predict anastomotic leaks. Several studies have concluded that patient-related factors (i.e. male, age >60 yr, smoking and nutritional deficiencies) and procedure-related factors (i.e. open vs laparoscopic approach, prolonged operating time and location of the anastomosis) contribute to anastomotic leaks (Table 5) . 52 54 58 More than two decades ago Mastboom showed that ibuprofen and piroxicam reduced hydroxyproline concentrations in anastomotic specimens of rodents. 59 More recent experimental studies indicate that NSAIDs can interfere with the mechanisms necessary to facilitate visceral anastomotic healing (e.g. reduced vascular endothelial growth factor synthesis, epithelial cell and granulocyte migration inhibition, and reduced crypt survival and collagen formation). [60] [61] [62] [63] As a result, the tensile strength and bursting pressure of the anastomosis are lower in animals treated with NSAIDs than those treated with placebo or nonNSAIDs analgesics (Figure 3 ). 63 64 29 In another large cohort study, patients enrolled in the Swedish Colorectal Cancer Registry were not at risk of anastomotic leak after the perioperative administration of NSAIDs for rectal cancer surgery. 28 In agreement with that investigation, Karlsson and colleagues 32 showed no association between the use of NSAIDs and anastomotic leaks after rectal cancer surgery. The impact of NSAIDs use on anastomotic leak has also been investigated in upper gastrointestinal cancers. Parzefall and colleagues 34 found no association between the use of diclofenac and anastomotic leaks after hypopharyngeal surgery. Several authors examined the impact of selective COX-2 inhibitors on anastomotic leaks. Holte and colleagues 31 showed in a retrospective study that celecoxib was an independent predictor of anastomotic leaks in patients who had colonic surgery. On the contrary, Gorissen and colleagues 67 and Raju and colleagues 33 could not demonstrate the association. 31 33 67 In fact, the authors indicated that the risk of anastomotic leaks was higher after the use of non-selective NSAIDs than with coxibs. 33 66 In a more recent observational study, Zittel and colleagues 23 showed that etoricoxib was an independent risk factor for postoperative complications but not anastomotic leaks. Three meta-analyses assessed the impact of NSAIDs on anastomotic leaks. Burton result of a lack of statistical power or high heterogeneity between the studies. Another meta-analysis of RCTs also demonstrated no association between the use of NSAIDs and anastomotic leaks. Contrary to that finding, pooled data from observational studies suggested an association between NSAIDs and anastomotic leaks. 17 19 20-22 69 A recent meta-analysis that combined data from RCTs and cohort studies concluded that the risk of an anastomotic leak was doubled in patients receiving NSAIDs; however, the authors identified selection bias in all the included studies. 70 Also, two studies accounted for 89% of the weight, although the direction of the findings in all of the studies was the same (i.e. not favouring NSAIDs). 70 Further complicating matters, the pattern of NSAIDs prescription was highly variable among different studies or even within the same work. 71 It is important to highlight that none of the meta-analyses contained pooled data from RCTs designed to test the hypothesis that the perioperative use of NSAIDs is associated with anastomotic leaks. Furthermore significant methodological issues (i.e. variability in patient population, type, dose and duration of NSAID use, and types of cancers) in the included studies should be taken into consideration before drawing conclusions on those investigations. 72 In summary, our analysis indicates that the role of NSAIDs in the development of anastomotic leaks after gastrointestinal cancer surgery is conflicting. The risk appears to be higher with the use of diclofenac and celecoxib. 30 35 67 73 Their dosage and time of initiation might also be important in the pathogenesis of the anastomotic leaks. Early perioperative administration (within 48 h) and high doses of diclofenac (>100 mg) and celecoxib (>200 mg) appears to have a larger impact on anastomotic leaks formation than a later administration and small doses. 73 Due to the widespread use of celecoxib (200-400 mg) in colorectal surgery, a large RCT in rectal cancer patients should be conducted.
Perioperative NSAIDs and cancer recurrence
The perioperative period has been long recognized as a time of increased risk of progression of the so-called minimal residual disease. 1 2 74 The rate of recurrence after surgery is highly variable among different cancers and can be influenced by patient (i.e. gender and age), procedure (i.e. postoperative complications or perioperative blood transfusions) and cancer-related (i.e. staging) factors. 75 76 Thus, any perioperative intervention should consider these factors. NSAIDs may prolong the recurrence-free survival of patients after cancer surgery by three distinct mechanisms (Figure 4) . First, if we account for the fact that circulating tumour cells and micrometastasis (part of the minimal residual disease) may still be present after negative-margin tumour excision, 74 and COX-2 is highly expressed in a broad range of cancers, NSAIDs can reduce postoperative tumour burden by having a direct effect on cancer cells. 77 For instance, celecoxib has been shown to inhibit surgery-induced metastasis formation in an animal model of colorectal cancer by inhibiting the prostaglandin E2 (PGE2)-glycogen synthase kinase-B catenin pathway. 78 Second, inflammation plays a significant role in the metastatic process. Thus, any strategy that modulates the systemic and local inflammatory response associated with surgery would be critical to prevent the escape of neoplastic cells from immunosurveillance in the tumour microenvironment. 79 80 The antiinflammatory effects of NSAIDs in cancer surgery have been well established. A recent RCT has demonstrated that the administration of flurbiprofen to women undergoing breast cancer surgery not only decreases opioid consumption but also reduces the circulating concentrations of tumour necrosis factor-a, interleukin-b and vascular endothelial growth factor. 81 Hiller and colleagues 82 have shown that the perioperative administration of celecoxib 400 mg preoperative followed by 200 mg twice daily for 5 days postoperatively slightly decreases the plasma concentration of PGE2 after major intracavity cancer surgery. The immune system, mainly cell-mediated immunity, is essential to eliminate cancer cells that have avoided intrinsic tumour suppression. 83 Moreover, metastatic tumour dissemination models have indicated that surgery produces a quantitative and qualitative reduction of natural killer (NK) cell cytotoxicity and that pharmacological blockade (beta-blockers and NSAIDs) of the inflammatory responses reduces the retention of adenocarcinoma cells in the lung and liver in an NK-dependent manner. [84] [85] [86] In support of these findings, the postoperative reduction of lymphocytes T CD4þ and NK cells in patients undergoing gastric and breast cancer procedures was less profound with the use of pre-emptive flurbiprofen and lornoxicam, respectively. 87 88 Contrary to this, the perioperative administration of parecoxib to women undergoing breast cancer surgery did not prevent the increase in T regulatory lymphocytes. 89 Lastly, NSAIDs have significant opioid-sparing effects. Opioids have been implicated in postoperative cancer recurrence by stimulating proliferation of cancer cells expressing the mu-opioid receptor and indirectly inducing immunosuppression. The impact of opioids on tumour growth appears to be more relevant in the perioperative period as their administration in the non-operative setting has not been linked to cancer recurrence. For instance, a recent study demonstrates that opioid given to women with breast cancer immediately after diagnosis did not have an impact on cancer recurrence. 90 One of the mechanisms by which opioids can facilitate metastasis formation is through the activation of intracellular signalling pathways that stimulate epithelial-mesenchymal transformation. 91 Experimental data suggest that cancer cells with mesenchymal features might be more sensitive to COX inhibition than cells with epithelial characteristics. 92 In support of this evidence, COX-1/COX-2 inhibition by indomethacin has shown to decrease the mRNA expression of the epidermal growth factor receptor, which is an essential mediator of some of the protumoral effects of opioids. 93 We found two RCTs that have assessed the effects of selective COX-2 inhibitors on cancer recurrence (Table 4) . 36 37 Both the studies were stopped before completion of recruitment because of concerns related to cardiovascular toxicities. Three retrospective studies investigated the association between selective COX-2 inhibitors and cancer recurrence or survival after major cancer surgery. While meloxicam and celecoxib improved the survival of patients with hepatocarcinoma and head and neck cancers, respectively, the use of the administration of celecoxib to patients with non-small cell lung cancer did not show any beneficial impact on their recurrence-free survival. 41 42 47 Most of the retrospective studies that have reported that the use of non-selective NSAIDs is associated with longer recurrence-free survival and overall survival after breast, colorectal, head and neck, hepatorcarcinoma and renal cell cancer surgery have also shown variations in dosage and timing of initiation of the NSAIDs (Table 4) . 4 38 40-43 47 Retsky and collegues 45 46 postulated that early relapses after breast cancer surgery are secondary to postoperative inflammation and that the early use of ketorolac at the time of surgery could be of particular benefit. In support of this hypothesis, the administration of ketorolac or diclofenac was associated with a 43% and 65% reduction in risk of recurrence and death after breast cancer surgery but not when NSAIDs were given after the diagnosis. 4 94 Perioperative administration of NSAIDs (e.g. ibuprofen, ketorolac) was not associated with improvement in survival after nonsmall cell lung cancer and tongue cancer. 42 44 95 Forget and colleagues 39 could not demonstrate an association between the intraoperative use of ketorolac and longer biochemical-free survival after radical prostatectomy. The role of aspirin in postoperative cancer recurrence has been investigated in the setting of colorectal and breast cancer. 48 49 After adjusting for several covariables, the postoperative use of aspirin decreased the risk of recurrence and death by 62%. 48 In another study, the administration of aspirin during preoperative chemoradiation therapy for rectal cancer was associated with better progression-free survival and overall survival but not after breast cancer diagnosis. 94 These findings highlight the importance of early initiation of NSAIDs and the complexity of results from one cancer to another. the impact of NSAIDs on cancer recurrence after oncological surgery. Currently, four RCTs (NCT00888797, NCT02141139, NCT00502684 and NCT01806259, clinicaltrials.gov) are being conducted to test the hypothesis of whether the perioperative administration of NSAIDs has an impact on cancer recurrence. NCT00502684 is a double-blind RCT enrolling patients (n¼32) with breast cancer to receive propranolol 40 mg day -1 and etodolac 800 mg day -1 , starting 3 days before surgery and continuing for 6 days after surgery. Unfortunately, this trial might be underpowered to determine the efficacy of etodolac on survival.
NCT02141139 is an open-label RCT testing the efficacy of ketorolac (before surgery) and ibuprofen (for 6 days after surgery) in breast cancer patients. NCT00888797 is a double-blinded placebo controlled RCT in patients (n¼400) undergoing colon cancer surgery who are randomized to receive etodolac (1600 mg day -1 ) and propranolol (40 mg day -1 ) vs placebo 5 days before surgery, on the day of surgery, and 14 days postoperatively. The primary outcome of that study is cancer recurrence. Lastly, NCT01806259 is investigating the effect of intraoperative ketorolac (30 mg) on recurrence-free survival after triple negative breast cancer surgery.
Conclusions
The current evidence is equivocal regarding the risks and benefits of short-term NSAIDs use in patients undergoing major cancer surgery. There is significant heterogeneity among the studies assessing the effects of NSAIDs on anastomotic leak after abdominal cancer surgery as well as those evaluating recurrence after cancer surgery. It cannot be expected that a single, large RCT will answer the questions of whether NSAIDs can increase the risk of anastomotic leaks and/or decrease postoperative cancer recurrence. Therefore, cancer-specific and procedurespecific, as well as drug, duration, timing and dose-specific RCTs will be needed to answer these questions. 71 It is important to highlight the role of big data analyses to carefully assess the associations and create predictive models around specific questions. It is possible to speculate that aggregating 'omics' data into perioperative registries will also contribute to identifying the role of NSAIDs in postoperative cancer recurrence.
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